First Time Loading...

Lyra Therapeutics Inc
NASDAQ:LYRA

Watchlist Manager
Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc
NASDAQ:LYRA
Watchlist
Price: 4.72 USD -8.7% Market Closed
Updated: Apr 29, 2024

Intrinsic Value

LYRA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. [ Read More ]

The intrinsic value of one LYRA stock under the Base Case scenario is 1.61 USD. Compared to the current market price of 4.72 USD, Lyra Therapeutics Inc is Overvalued by 66%.

Key Points:
LYRA Intrinsic Value
Base Case
1.61 USD
Overvaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Lyra Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling LYRA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Lyra Therapeutics Inc

Provide an overview of the primary business activities
of Lyra Therapeutics Inc.

What unique competitive advantages
does Lyra Therapeutics Inc hold over its rivals?

What risks and challenges
does Lyra Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Lyra Therapeutics Inc recently?

Summarize the latest earnings call
of Lyra Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lyra Therapeutics Inc.

Provide P/S
for Lyra Therapeutics Inc.

Provide P/E
for Lyra Therapeutics Inc.

Provide P/OCF
for Lyra Therapeutics Inc.

Provide P/FCFE
for Lyra Therapeutics Inc.

Provide P/B
for Lyra Therapeutics Inc.

Provide EV/S
for Lyra Therapeutics Inc.

Provide EV/GP
for Lyra Therapeutics Inc.

Provide EV/EBITDA
for Lyra Therapeutics Inc.

Provide EV/EBIT
for Lyra Therapeutics Inc.

Provide EV/OCF
for Lyra Therapeutics Inc.

Provide EV/FCFF
for Lyra Therapeutics Inc.

Provide EV/IC
for Lyra Therapeutics Inc.

Show me price targets
for Lyra Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Lyra Therapeutics Inc?

How accurate were the past Revenue estimates
for Lyra Therapeutics Inc?

What are the Net Income projections
for Lyra Therapeutics Inc?

How accurate were the past Net Income estimates
for Lyra Therapeutics Inc?

What are the EPS projections
for Lyra Therapeutics Inc?

How accurate were the past EPS estimates
for Lyra Therapeutics Inc?

What are the EBIT projections
for Lyra Therapeutics Inc?

How accurate were the past EBIT estimates
for Lyra Therapeutics Inc?

Compare the revenue forecasts
for Lyra Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lyra Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lyra Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lyra Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Lyra Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Lyra Therapeutics Inc with its peers.

Analyze the financial leverage
of Lyra Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Lyra Therapeutics Inc.

Provide ROE
for Lyra Therapeutics Inc.

Provide ROA
for Lyra Therapeutics Inc.

Provide ROIC
for Lyra Therapeutics Inc.

Provide ROCE
for Lyra Therapeutics Inc.

Provide Gross Margin
for Lyra Therapeutics Inc.

Provide Operating Margin
for Lyra Therapeutics Inc.

Provide Net Margin
for Lyra Therapeutics Inc.

Provide FCF Margin
for Lyra Therapeutics Inc.

Show all solvency ratios
for Lyra Therapeutics Inc.

Provide D/E Ratio
for Lyra Therapeutics Inc.

Provide D/A Ratio
for Lyra Therapeutics Inc.

Provide Interest Coverage Ratio
for Lyra Therapeutics Inc.

Provide Altman Z-Score Ratio
for Lyra Therapeutics Inc.

Provide Quick Ratio
for Lyra Therapeutics Inc.

Provide Current Ratio
for Lyra Therapeutics Inc.

Provide Cash Ratio
for Lyra Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Lyra Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Lyra Therapeutics Inc?

What is the current Free Cash Flow
of Lyra Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lyra Therapeutics Inc.

Financials

Balance Sheet Decomposition
Lyra Therapeutics Inc

Current Assets 104.8m
Cash & Short-Term Investments 102.8m
Other Current Assets 2.1m
Non-Current Assets 37.8m
PP&E 35.3m
Other Non-Current Assets 2.5m
Current Liabilities 19.6m
Accounts Payable 3.1m
Accrued Liabilities 14.8m
Other Current Liabilities 1.7m
Non-Current Liabilities 33.6m
Other Non-Current Liabilities 33.6m
Efficiency

Earnings Waterfall
Lyra Therapeutics Inc

Revenue
1.6m USD
Operating Expenses
-67.1m USD
Operating Income
-65.5m USD
Other Expenses
2.8m USD
Net Income
-62.7m USD

Free Cash Flow Analysis
Lyra Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

LYRA Profitability Score
Profitability Due Diligence

Lyra Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 1-Year Revenue Growth
Declining ROE
24/100
Profitability
Score

Lyra Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

LYRA Solvency Score
Solvency Due Diligence

Lyra Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Lyra Therapeutics Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LYRA Price Targets Summary
Lyra Therapeutics Inc

Wall Street analysts forecast LYRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LYRA is 12.24 USD with a low forecast of 10.1 USD and a high forecast of 15.75 USD.

Lowest
Price Target
10.1 USD
114% Upside
Average
Price Target
12.24 USD
159% Upside
Highest
Price Target
15.75 USD
234% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

LYRA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

LYRA Price
Lyra Therapeutics Inc

1M 1M
-24%
6M 6M
+54%
1Y 1Y
+82%
3Y 3Y
-54%
5Y 5Y
-75%
10Y 10Y
-75%
Annual Price Range
4.72
52w Low
2.43
52w High
6.53
Price Metrics
Average Annual Return -43.92%
Standard Deviation of Annual Returns 12.8%
Max Drawdown -89%
Shares Statistics
Market Capitalization 270.1m USD
Shares Outstanding 59 743 100
Percentage of Shares Shorted 0.82%

LYRA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Lyra Therapeutics Inc Logo
Lyra Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

270.1m USD

Dividend Yield

0%

Description

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The company is headquartered in Watertown, Massachusetts and currently employs 53 full-time employees. The company went IPO on 2020-05-01. The firm is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

Contact

MASSACHUSETTS
Watertown
480 Arsenal Street
+16173734600.0
https://lyratherapeutics.com/

IPO

2020-05-01

Employees

53

Officers

Executive Chairman
Dr. Harlan W. Waksal M.D.
CEO, President & Director
Dr. Maria Palasis Ph.D.
Chief Technology Officer
Dr. John E. Bishop Ph.D.
Co-Founder
Dr. Carmichael S. Roberts Jr., Ph.D.
CFO, Treasurer & Secretary
Mr. Jason Cavalier
Vice President of Operations
Mr. Ray Knox
Show More
Senior Vice President of Investor Relations & Communications
Ms. Ellen Cavaleri
Chief Legal Officer
Mr. Ronan P. O'Brien J.D.
Senior Vice President of Commercial Strategy & Market Development
Ms. Corinne Noyes
Senior Vice President of Clinical Affairs
Ms. Vineeta Belanger Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one LYRA stock?

The intrinsic value of one LYRA stock under the Base Case scenario is 1.61 USD.

Is LYRA stock undervalued or overvalued?

Compared to the current market price of 4.72 USD, Lyra Therapeutics Inc is Overvalued by 66%.